288 completed, 186 active not recruiting, 139 terminated, 94 recruiting. 517 Phase 2, 324 Phase 1, 80 Phase 3, 16 Early Phase 1, 5 Phase 4.
Follow Opdivo: new trials by email Literature Review of Opdivo trials Research Report on Opdivo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC Nivolumab - Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 40 | 2026-11-02 | 2026-10-28 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2026-10-28 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Divarasib, Pembrolizumab, Nivolumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 400 | 2026-10-06 | 2026-11-09 |
| Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma Bmab1700, Opdivo - Melanoma | Phase 1 | Recruiting | Biocon Biologics UK PLC | 120 | 2026-09-09 | 2026-11-06 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases | Phase 1 / Phase 2 | Recruiting | Melanoma and Skin Cancer Trials Limited | 46 | 2026-08-31 | 2026-10-13 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas Pazopanib, Trabectedin, Ipilimumab - Soft Tissue Sarcomas | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-12 | 2026-08-06 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Fianlimab, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Recruiting | Brian Rini | 120 | 2026-04-29 | 2026-09-04 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody - Prostate Cancer Patients, Non-castrate Prostate Cancer | Phase 1 | Recruiting | University of Wisconsin, Madison | 14 | 2026-03-03 | 2026-03-11 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-12 | 2026-08-11 |
Showing 20 of 808. Sign in to see all of them.
Melanoma (116) · Carcinoma, Non-Small-Cell Lung (110) · Carcinoma, Renal Cell (81) · Lung Neoplasms (48) · Neoplasm Metastasis (43) · Squamous Cell Carcinoma of Head and Neck (41) · Neoplasms (40) · Carcinoma, Hepatocellular (39) · Colorectal Neoplasms (39) · Hodgkin Disease (28) · Carcinoma, Transitional Cell (25) · Pancreatic Neoplasms (25) · Head and Neck Neoplasms (23) · Stomach Neoplasms (23) · Urinary Bladder Neoplasms (23)
Bristol-Myers Squibb (102) · National Cancer Institute (NCI) (89) · M.D. Anderson Cancer Center (58) · Dana-Farber Cancer Institute (20) · H. Lee Moffitt Cancer Center and Research Institute (17) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17) · Emory University (16) · City of Hope Medical Center (14) · Washington University School of Medicine (12) · Mayo Clinic (11) · Northwestern University (11) · Jonsson Comprehensive Cancer Center (10) · Massachusetts General Hospital (7) · The Netherlands Cancer Institute (7) · University of Chicago (7)
United States (641) · Canada (99) · Spain (95) · Australia (93) · France (80) · Italy (73) · Germany (68) · United Kingdom (59) · Belgium (48) · Netherlands (47) · Poland (46) · Japan (42) · Argentina (37) · Russia (35) · Brazil (34)
Alex F Herrera (4) · Mariano Provencio, MD (4) · Sumanta K Pal (4) · Brigette B Ma (3) · Eric Jonasch, MD (3) · Project Leader (3) · Sant P Chawla, MD (3) · Sunyoung Lee (3) · A P Chen (2)
PMID 31401903, PMID 33058158, PMID 35383907, PMID 37505794, PMID 39462179, PMID 32691060, PMID 32852531, PMID 33394722, PMID 33526329, PMID 34272087, PMID 34385708, PMID 35031545, PMID 35622074, PMID 36648215, PMID 37146227, PMID 38155060, PMID 39777725, PMID 12377653, PMID 20530316, PMID 21239400, PMID 22590666, PMID 24089446, PMID 25482239, PMID 25631445, PMID 25650315, PMID 26410619, PMID 26586415, PMID 26773716, PMID 27234989, PMID 27269947, PMID 27410923, PMID 27528724, PMID 27718784, PMID 27923550, PMID 28223062, PMID 28295222, PMID 28734759, PMID 28916527, PMID 29257710, PMID 29355075, PMID 29370992, PMID 29490632, PMID 29562145, PMID 29584545, PMID 29602646, PMID 29628312, PMID 29658845, PMID 29669604, PMID 29692997, PMID 29784747
2016 (26), 2018 (21), 2017 (17), U10CA180820 (17), U10CA180821 (14), P30CA033572 (11), P30CA060553 (11), P30CA138292 (11), U10CA180888 (11), U10CA180868 (10), 2023 (9), 2015 (7), UM1CA186691 (7), UM1CA186709 (6), U10CA180886 (5)